Skip to content

EBIT at other companies

Eli Lilly logo
Eli LillyLLY
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
AbbVie logo
AbbVieABBV
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
Arrowhead Research logo
Arrowhead ResearchARWR
IQVIA logo
IQVIAIQV

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Calculated from Apogee Therapeutics, Inc.’s reported figures.

Plus components not separately reported this period.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s EBIT?
Apogee Therapeutics, Inc. (APGE) reported EBIT of -$82.77M in Q1 2026.
How has Apogee Therapeutics, Inc.'s EBIT changed year-over-year?
Apogee Therapeutics, Inc.'s EBIT decreased by 31.2% year-over-year, from -$63.1M to -$82.77M.
What is the long-term trend for Apogee Therapeutics, Inc.'s EBIT?
Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s EBIT has grown at a 75.2% compound annual growth rate (CAGR), from -$93M to -$285.6M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.